N/A N=169 European Study on Three Different Approaches to Managing Class 2 Cavities in Primary Teeth
Dental Caries
Primary: Failure Rate of the Three Treatment Arms Judged Clinically — 37; 31; 39; 2 Teeth — p=0.02
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=24 REducing Anxiety in CHildren Undergoing Procedures
Ambulatory Surgery
Primary: Change in Anxiety Scores With the Addition of the iPad Intervention-Comparing Group 1 to Group 2 — 25; 29.69; 28.82; 24.83 units on a scale
Phase 3 N=100 A Single-Center,Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle
Allergic Conjunctivitis
Primary: Ocular Itching at Duration of Action (8 Hours + 30 Minutes Post-dose) — 1.76; 2.69; 1.85; 2.74 units on a scale
N/A N=36 Tension of THERABAND® Kinesiology Tape on Shoulder Pain
Shoulder Pain
Primary: Numeric Pain Rating Scale (NPRS) — 5.458; 5.115; 4.708; 3.808 units on a scale
Phase 3 N=2,840 Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Breast Cancer
Primary: Invasive Disease-free Survival (iDFS) in Neratinib Arm Compared to Placebo Arm at Year 2 — 4.7; 7.5 percentage of participants with events — p=0.008
N/A N=100 Preference on the Feedback Mechanisms of Dose Delivery Confirmation With the Breezhaler® Device Compared to the Ellipta® Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Disease, Chronic Obstructive (COPD)
Primary: Patient's Preference on the Feedback Mechanisms of Dose Delivery Confirmation Using the Breezhaler® and Ellipta® Devices — 4.3; 3.6 units on a scale — p=<0.0001
Phase 2 N=20 Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma
Contiguous Stage II Grade 1 Follicular Lymphoma · Contiguous Stage II Grade 2 Follicular Lymphoma · Contiguous Stage II Grade 3 Follicular Lymphoma
Primary: Number of Participants With Adverse Events — 3; 9; 6; 1 Participants
Phase 2 N=217 Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma
Melanoma
Primary: Phase 1b: Number of Participants With Dose-limiting Toxicities — 0 Participants
Phase 4 N=14 Inhaled Nitric Oxide and Inhaled Prostacyclin After Cardiac Surgery for Heart Transplant or LVAD Placement
Heart Failure
Primary: Pulmonary Hypertension — 31.4; 29.1; 25.9; 25.4 mmHg
Phase 2 N=10 A Study to Assess the Safety of Single Doses of GSK189075 in Subjects With Type 1 Diabetes Mellitus
Diabetes Mellitus, Type 1
Primary: Number of Participants With All Adverse Events (AE) and Serious Adverse Events (SAE) — 3; 4; 5; 6 Participants
Phase 4 N=1,330 Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose
Tetanus · Diphtheria · Pertussis
Primary: Percentage of Participants With Diphtheria and Tetanus Seroprotection — 100.0; 100.0; 99.8; 99.4 Percentage of participants
N/A N=68 Targeted Levothyroxine Dosing in Infants With Congenital Hypothyroidism
Congenital Hypothyroidism
Primary: Dose Adjustments — 2.5; 2.4 Number of dose adjustments
Phase 3 N=2,174 A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)
Urinary Bladder Diseases · Urinary Bladder Overactive · Urologic Diseases
Primary: Change From Baseline to End of Treatment (EoT) in Mean Number of Incontinence Episodes Per 24 Hours — -1.8; -1.53; -1.67 incontinence episodes — p==0.001
Phase 2 N=498 Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working Seeds
Measles · Varicella · Mumps
Primary: Number of Subjects Seroconverted for Measles, Mumps, Rubella and Varicella Antibodies Greater Than or Equal to (≥) the Cut-off Value. — 312; 157; 279; 142 Participants
N/A N=79 Artemether-lumefantrine for Treatment of P. Falciparum Malaria in Brazil
Malaria
Primary: Absence of Malaria Parasites in Blood. — 73 Participants